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Background: Risperidone long-acting injectable (RLAI), the first
second-generation depot antipsychotic, has extensively been studied
before introduction. Thereafter, questions about the type of patients
actually treated with RLAI in daily practice remain to be answered
for making valid antipsychotic treatment comparisons involving
RLAI in observational studies.
Objective: We aimed to determine in chronic antipsychotic users
who switched treatment, predictors for the prescription of (1) depot
versus oral antipsychotics and (2) RLAI versus first-generation an-
tipsychotics (FGAs) depot.
Methods: We used pharmacy dispensing data from 53 community
pharmacies in the northeast of the Netherlands containing approx-
imately 500,000 persons. Chronic antipsychotic users were defined
and followed up for a switch in antipsychotic treatment within the
first period that RLAI was on the market. Multivariable analysis
was performed to relate patient, prescriber, and medication charac-
teristics to prescription of a new antipsychotic drug.
Results: Predictors for switching to depot versus oral antipsy-
chotics were male sex, previous use of depot antipsychotics, recent
anticholinergic drug use, and a gap in antipsychotic dispensation
history. Predictors for switching to RLAI versus FGA depot were
previous use of depot and consulting a specialist.
Conclusions: The results suggest that, compared with oral anti-
psychotics, patients receiving a depot are less compliant users,
with more extrapyramidal side effects. Compared with FGA depot,
patients receiving RLAI tend to be more severely ill patients. We
conclude that RLAI may be partly channeled to patients as a last
resort, which may have important consequences for the interpre-
tation of observational effectiveness comparisons between RLAI
and other antipsychotics in daily practice.
(J Clin Psychopharmacol 2008;28:625–630)
Schizophrenia, with a lifetime prevalence of approximately1.0%,1 is one of the most devastating mental illnesses
with severe physical, social, and economic consequences.2
Primary cost drivers in schizophrenia are relapse and re-
hospitalization and are closely related to low compliance with
therapy.3–6
Since the introduction in the 1950s of the now called
first-generation antipsychotics (FGAs), medication is the
cornerstone in the treatment of schizophrenia. Second-
generation antipsychotics (SGAs), which were developed
in the 1990s, were initially believed to be superior in med-
ication adherence because of their lower rate of neurolo-
gical side effects.7 Meta-analyses have shown that, with
SGAs, dropout rates are not lower than with first-generation
ones.8 The supposed superiority may partly be based on
registration studies that compare SGA with higher than
nowadays recommended doses of FGAs.8,9 The rates of
relapse are modestly but significantly lower with the newer
second-generation drugs.10
A depot antipsychotic aims at promoting compliance
in people with particularly severe mental illnesses, thereby
enhancing relapse prevention.11–16 Several studies showed
advantages of a depot regarding rates and durations of re-
hospitalization compared with oral antipsychotics.11 Guide-
lines recommend considering depot antipsychotics in
patients with repeated nonadherence.17 Until the 2000s,
only FGAs, such as haloperidol and zuclopenthixol, were
available as long-acting depots. Risperidone long-acting
injectable (RLAI) is the first and, at the time of our study,
only SGA in depot formulation and is available in the
Netherlands since May 2003.
In the efficacy studies on RLAI, the type of patients
may have represented a selection of the population that will
eventually be treated in routine clinical practice. Therefore, it
is largely unknown what the real-life benefits and risks are
compared with other antipsychotics with similar indications.
Such postmarketing comparisons between medications are
almost always made using observational study designs. Con-
sequently, adjustment for the type of patients who receive the
medications under study is essential for reasons of validity.
In addition, models used for pharmacoeconomic evaluation
were often based on assumptions rather than actual data about
drug prescription in daily practice.18,19 Thus, questions about
the type of patients who are actually treated with RLAI need
to be answered.
The aim of the present study was 2-fold. First, we
aimed to determine predictors for the prescription of depot
versus oral antipsychotics in patients who had a medication
switch during long-term antipsychotic treatment. Second,
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within the patients receiving a depot antipsychotic, we aimed
to determine predictors for the prescription of RLAI versus
FGA depot. For the analyses of these predictors, data on
pharmacy-based prescription drug histories from the target
population were used.
MATERIALS AND METHODS
The present study was performed using data from the
InterAction DataBase (www.iadb.nl). This database provides
anonymous data on drug prescription from 53 pharmacists in
a dynamic population of approximately 500,000 residents of
the northern and eastern provinces of the Netherlands from
1994 onward. Besides demographical data, such as date of
birth and sex, several aspects of pharmacotherapy can be
derived from the prescription records. Diagnoses are not
included in this database.
Chronic users of antipsychotics were included in the
study population. In InterAction DataBase, men and women
younger than 65 years on May 1, 2001, were defined as
chronic users if they received at least 1 prescription for an
antipsychotic drug in each year of the 2-year period from
May 1, 2001, to April 30, 2003. By doing so, we aimed to
include representatives of our target population, that is,
chronic schizophrenic patients. Because the actual diagnoses
were unknown, we tried to achieve this by making restrictions
as to age and comedication. A maximum age was set to
exclude elderly getting antipsychotic drugs for indications
other than schizophrenia, for example, delirium. A lower age
limit was set at 12 years to prevent inclusion of children
treated with antipsychotics for, among others, attention-
deficit/hyperactivity disorder. Lithium users were excluded
to exclude patients with bipolar disorder.
We followed up chronic antipsychotic users over time
from May 1, 2003, until December 31, 2005, for a switch to a
not previously used oral antipsychotic or depot antipsychotic,
the latter being FGA depot or RLAI. A switch to a not
previously used specific antipsychotic was defined if the first
prescription of that antipsychotic occurred from May 1, 2003,
onward, and was not prescribed in the period May 1, 2001, to
April 30, 2003. The oral and depot preparations of a specific
FIGURE 1. Flowchart of the study population, including the 2 comparisons of the study: depot versus oral antipsychotics, and
RLAI versus first-generation depot antipsychotics (FGA depot).
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antipsychotic drug were analyzed as different antipsychot-
ics. Thus, a patient who always used oral haloperidol and
switched to haloperidol depot after May 1, 2003, was con-
sidered as switching to a not previously used antipsychotic,
that is, FGA depot. The first prescription date of the new
treatment was defined as the index date. In case of more
than 1 switch to a new antipsychotic drug per patient in the
follow-up period, one of these treatments was randomly
selected for the analysis. One-time use of the corresponding
oral formulation just before a depot antipsychotic was started,
which is common when starting a depot antipsychotic, was
not counted as a switch to a new oral antipsychotic.
For each new user, we assessed several potential
predictors of use. First, we assessed sex, age at index date,
and the prescriber who initiated the new treatment (general
practitioner [GP] or specialist). Second, as a marker for recent
disease severity, use of psychotropic comedication (anxio-
lytics [ATC N05B], hypnotics/sedatives [ATC N05C], and
antidepressants [ATC N06A]) and, as a marker for extra-
pyramidal side effects, use of anticholinergic drugs (ATC
N04A) were determined in the 3 months preceding the index
date. Third, in the 2 years preceding the index date, the
number of different antipsychotic drugs used, use of depot
antipsychotics, and the presence of a gap of 3 months or
more in antipsychotic dispensing history were determined. A
gap of 3 months or more in dispensing occurrences of an-
tipsychotic drugs was used as a measure for reduced com-
pliance. The size of the gap was based on the fact that
antipsychotics are prescribed for, at most, 3 months in the
Netherlands.
We first studied potential predictors of a switch to an
oral antipsychotic as compared with a switch to a depot an-
tipsychotic. Next, within the group of depot users, we studied
predictors of a switch to RLAI as compared with a switch to
FGA depot. Odds ratios (ORs) with 95% confidence intervals
(95% CIs) were calculated as measures of relative risk.
Multivariable logistic regression analysis was used to adjust
for age and sex. Of note is that, in this study, predictors of
switching to a new therapy itself are ruled out because the
results are conditional on switching.
RESULTS
We identified a total of 2491 eligible subjects as
chronic antipsychotic users, and they formed our study
cohort. During observation period, a total of 652 users
(26.2%) switched to a not previously used antipsychotic
drug. Forty patients (6.1%) of these 652 switched to an oral
as well as a depot antipsychotic. After random assignment
of the patients who switched more than once, 110 patients
were classified as switching to a depot antipsychotic, and
542 patients were classified as switching to an oral anti-
psychotic. Figure 1 shows a flowchart describing the study
population.
TABLE 1. Frequency of the Characteristics of Switchers to Oral and to Depot Antipsychotics
Oral Antipsychotic (n = 542) Depot Antipsychotic (n = 110) RLAI (n = 56) FGA Depot (n = 54)
n % n % n % n %
Sex
Female 247 45.6 43 39.1 22 39.3 21 38.9
Age category, yrs
<30 103 19.0 26 23.6 15 26.8 11 20.4
30–50 313 57.7 49 44.5 20 35.7 29 53.7
51+ 126 23.2 35 31.8 21 37.5 14 25.9
Prescriber
GP 153 28.2 25 22.7 6 10.7 19 35.2
Specialist 389 71.8 85 77.3 50 89.3 35 64.8
3 mo preceding new antipsychotic
Comedication
Use of sedatives/hypnotics 135 24.9 17 15.5 10 17.9 7 13.0
Use of anxiolytics 222 41.0 37 33.6 18 32.1 19 35.2
Use of antidepressants 216 39.9 22 20.0 12 21.4 10 18.5
Any of psychotropic medication above 348 64.2 49 44.5 25 44.6 24 44.4
Use of anticholinergics 59 10.9 32 29.1 19 33.9 13 24.1
2 yrs preceding new antipsychotic
Prior use of depot 41 7.6 37 33.6 25 44.6 12 22.2
No. different antipsychotics used
1 361 66.6 61 55.4 31 55.3 30 55.6
2 or more 181 33.4 49 44.6 25 44.7 24 44.4
Gap of Q3 mo 216 39.9 69 62.7 32 57.1 37 68.5
Depot users are divided in RLAI and first-generation depot antipsychotics (FGA depot).
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Risperidone long-acting injectable accounted for ap-
proximately half (n = 56) of all new depot users. From the
new users of FGA depot (n = 54), zuclopenthixol (n = 20)
was the most frequently dispended depot antipsychotic,
followed by haloperidol (n = 12), flupenthixol (n = 10),
fluphenazine (n = 6), perphenazine (n = 3), bromperidol
(n = 2), and fluspirilene (n = 1). Table 1 summarizes the
characteristics of the new users of the different groups of
antipsychotics.
In Table 2, ORs for the predictors of new users of depot
antipsychotics as compared with new users of oral antipsy-
chotics are displayed. The age and prescriber distribution did
not differ significantly between these users. Compared with
new users of oral antipsychotics, users of depot antipsy-
chotics less often were female (OR, 0.54; 95% CI, 0.35–0.82)
and more often received an anticholinergic drug before the
index date (OR, 3.52; 95% CI, 2.12–5.84). Depot antipsy-
chotics were approximately 2 times less frequently prescribed
to patients who recently used psychotropic comedication
(OR, 0.49; 95% CI, 0.32–0.75), especially antidepressants
(OR, 0.41; 95% CI, 0.25–0.68). Depot antipsychotics were
more often prescribed to patients who had a gap of 3 or
more months in their prescription data (OR, 2.49; 95% CI,
1.62–3.85). Finally, depot antipsychotics were around 6 times
more frequently prescribed to patients who had been
prescribed a depot antipsychotic before (OR, 5.78; 95% CI,
3.44–9.71) and to patients in which the number of different
used oral antipsychotics before was higher (OR, 1.63; 95%
CI, 1.07–2.48).
Also in Table 2, ORs from the predictors of new
users of RLAI as compared with new users of FGA depot
are shown. Compared with FGA depot, RLAI was more of-
ten prescribed by specialists (OR, 4.88; 95% CI, 1.72–13.70)
and to patients who had been prescribed a depot before (OR,
2.76; 95% CI, 1.17–6.49). There was no significant differ-
ence in the other characteristics.
DISCUSSION
In our study, chronic antipsychotic drug users who
switched to a depot formulation, more often were male, had
more frequently used anticholinergic drugs before, had less
often used psychotropic comedication before, and had more
gaps in their antipsychotic prescription history compared
with those who switched to an oral antipsychotic. Further-
more, depot antipsychotics were predominantly prescribed to
patients who had used depot antipsychotics before. Users of
RLAI had similar profiles as FGA depot users, except for 2
characteristics. Patients who used a depot antipsychotic
TABLE 2. Predictors for Switching to (1) a New Treatment With a Depot Versus an Oral Antipsychotic and (2) a New Treatment
With RLAI Versus FGA Depot in Chronic Antipsychotic Users
Depot (n = 110) vs Oral Antipsychotics (n = 542) RLAI (n = 56) vs FGA Depot (n = 54)
Univariable Multivariable Univariable Multivariable
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Sex
Female 0.54 0.35–0.82 1.02 0.47–2.19
Age category, yrs
<30 1.0 1.0
30–50 0.62 0.37–1.05 0.51 0.19–1.33
51+ 1.10 0.62–1.95 1.10 0.39–3.08
Prescriber
GP 1.0 1.0 1.0 1.0
Specialist 1.34 0.82–2.17 1.44 0.88–2.36 4.52 1.64–12.50 4.88 1.72–13.70
3 mo preceding new antipsychotic
Comedication
Use of sedatives/hypnotics 0.55 0.32–0.96 0.62 0.35–1.10 1.46 0.51–4.16 1.32 0.42–4.11
Use of anxiolytics 0.73 0.48–1.12 0.78 0.51–1.21 0.87 0.40–1.93 0.87 0.39–1.96
Use of antidepressants 0.38 0.23–0.62 0.41 0.25–0.68 1.20 0.47–3.06 1.11 0.43–2.93
Any of psychotropic medication above 0.45 0.30–0.68 0.49 0.32–0.75 1.00 0.48–2.14 1.00 0.48–2.14
Use of anticholinergics 3.36 2.05–5.50 3.52 2.12–5.84 1.62 0.70–3.73 1.78 0.75–4.23
2 yrs preceding new antipsychotic
Prior use of depot 6.19 3.73–10.29 5.78 3.44–9.71 2.82 1.23–6.47 2.76 1.17–6.49
No. different used antipsychotics
1 1.0 1.0 1.0 1.0
2 or more 1.60 1.06–2.43 1.63 1.07–2.48 1.00 0.48–2.14 0.99 0.46–2.13
Gap of Q3 mo 2.54 1.66–3.88 2.49 1.62–3.85 0.75 0.24–2.33 0.63 0.28–1.45
Multivariable analysis was corrected for age and sex. Statistically significant predictors are shown in bold font.
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before, and who consulted a psychiatrist rather than a GP,
were more likely to be prescribed RLAI than FGA depot.
Some potential limitations of our study should be
mentioned. We used gaps of 3 months or more in anti-
psychotic drug history as a proxy for medication compli-
ance. This is, however, a somewhat dual parameter, because
it can point to noncompliance or it can point to (re)hospital-
ization. Data of hospital prescriptions, however, were not
available. Nevertheless, both causes of a gap indicate de-
terioration of the patient. Another reason for a gap in
prescription could be the result of Btargeted treatment[ in
which a patient stops his medication after a certain psychosis-
free period and starts again when he or she has a new
psychosis. A gap from this cause may be indicative of a
temporary improvement of the patient. However, we consider
a gap of 3 months or more on average being a measure of
noncompliance. Unfortunately, unambiguous information on
compliance to therapy and underlying disease cannot be
derived from pharmacy prescription data. Furthermore, we
were unable to assess other relevant prognostic clinical
characteristics such as the number of prior psychotic
episodes, direct clinical measures such as the Clinical Global
Impression scale or Positive and Negative Syndrome Scale,
or the reason for switching. Although we had no data on the
diagnoses of the patients in our study, the far majority must
have been experiencing schizophrenia.20 Finally, we limited
the study population to those subjects receiving antipsychotic
medication during a 2-year period to select chronic users.
Because first-episode patients who have been clinically stable
for 1 year may have undergone a trial of discontinuation of
antipsychotics, which is put forward as an option in Dutch
guidelines, these patients may be underrepresented in our
study.
Our results indicate that depot antipsychotics are
prescribed to patients who had adherence problems toward
their oral medication and more frequent or more severe
extrapyramidal side effects. These findings are in line with
our a priori expectations. First, following the guidelines,17
extrapyramidal side effects are one of the main reasons to
change antipsychotic treatment. One of the possible benefits
of a depot antipsychotic is that a stable, low dose can be
sustained, with less side effects as a result.16,21 Indeed, the
higher prescription rate of anticholinergics in the 3 months
before the switch in users of depot is in line with this notion.
Second, a gap in prescription history may be a sign of
noncompliance, which is the main reason to switch to a depot
antipsychotic. With a depot antipsychotic, compliance to
therapy can be improved.11–15 Thus, a higher number of
prescription gaps is what we expected in the group of new
users of depot antipsychotics compared with oral antipsy-
chotics. Interestingly, male patients are also more likely to be
prescribed depot antipsychotics than female patients. An
explanation could be that men with schizophrenia have a
poorer prognosis and outcome than women,1 needing more
different medication strategies. It can be hypothesized that
men are thought to have a lower compliance than women,
although this cannot be confirmed by empirical evidence.22
One could expect that new users of depot antipsychotics are
not only less compliant patients but also more severely ill
patients than new users of oral antipsychotics. However, this
expectation was not supported by our data because the use of
psychotropic comedication was not associated with switching
to depot antipsychotics.
The difference in prior use of depot between RLAI and
FGA depot users suggests that RLAI is especially prescribed
to patients not responding satisfactorily to FGA depot, the
latter being suggestive of more severe illness. Also, patients
with schizophrenia treated with first-generation depot anti-
psychotics have been shown to use more alcohol and illicit
substances and to show higher levels of psychopathology.23
Our finding that switching to RLAI is more likely than to
FGA depot when a specialist is the prescriber is also in line
with channeling of RLAI to the more severely ill patients. An
alternative explanation for the difference in prescriber
between FGA depot and RLAI that cannot be excluded is
that specialists were more familiar with the existence of
RLAI after its introduction than were GPs. Also corroborat-
ing our findings is the study of Niaz and Haddad,24 where
patients prescribed RLAI had significantly higher baseline
rates of drug misuse, unemployment, and forensic markers
than control patients prescribed oral antipsychotics. The
increasing evidence suggesting that RLAI is channeled to
the more severely ill patient may have important consequen-
ces for the validity of comparisons between RLAI and other
groups of antipsychotics in observational studies.25
In our study, a relatively small number of chronic
antipsychotic users switched to a depot antipsychotic. This
concurs with observations by others21,26 that depot antipsy-
chotics, despite their potential advantages, are still not much
prescribed in the treatment of schizophrenia. This limited use
of depot antipsychotic medication may be due to the
introduction of the oral SGAs in the 1990s,21 leading to a
less awareness of its diminished relapse rates, its reduced
durations of hospitalizations,11,16 and its well acceptance by
experienced patients.27 Heres et al26 showed in their study on
attitudes of psychiatrists toward antipsychotic depot medi-
cation that the main reason not to choose a FGA depot was
the fear of extrapyramidal side effects. The main reason for
not prescribing RLAI was the assumed sufficient compliance
with an oral SGA.
In conclusion, depot antipsychotics are preferentially
prescribed to patients with adherence problems and more
extrapyramidal side effects, as compared with oral antipsy-
chotics. This is in accordance with therapeutic guidelines.17
Our data further indicate that, within depot users, RLAI is
largely channeled to the more severely ill patients who tried a
depot before, that is, RLAI is used as a last resort for many
users. These observations could have important consequences
for interpreting observational comparisons between groups of
antipsychotics.
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